Eosinophilic Esophagitis: What Works, What Doesn't?

Using FMT over standard-of-care therapy may significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.

Recurrent C difficile requires pulse vancomycin therapy; fecal microbiota transplant shows promise.

DDW 2025. Colonoscopic delivery of fecal therapy prevented recurrent C. diff infection in 95% of participants for 8 weeks, with mild GI adverse events reported by <10%.

The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.

Your daily dose of the clinical news you may have missed.

The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.